| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | — | — | — | — | — | — |
| Quick Ratio | — | — | — | — | — | — |
| Debt / Equity | 0.01 | — | — | — | 0.00 | 0.00 |
| ROE | -61.82% | -490.58% | -34.08% | -108.36% | -45.32% | -22.90% |
| ROA | -41.59% | -133.09% | -27.57% | -96.25% | -40.92% | -21.78% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book Value / Share | 0.25 | 0.07 | 0.31 | 0.26 | 0.53 | 0.78 |
Medicenna Therapeutics Corp. is a clinical-stage biotechnology company specializing in the development of advanced immunotherapies for cancer and other challenging diseases. Leveraging its proprietary Superkine Platform, Medicenna engineers powerful and highly selective interleukin-based therapeutics known as Superkines. These novel proteins are designed to precisely modulate and amplify the immune response, targeting key cellular pathways to enhance anti-tumor immunity or address autoimmune conditions. The company’s pipeline includes Superkines such as MDNA11, an engineered IL-2 variant optimized for cancer immunotherapy, and MDNA55, an IL-4 empowered cytotoxin developed for recurrent glioblastoma, a form of brain cancer. Additional candidates address various solid tumors and autoimmune diseases, utilizing mechanisms that either stimulate immune cell activity or inhibit disease-promoting cytokine signaling. Medicenna’s innovative technologies are geared toward tackling diseases with significant unmet need, emphasizing scientific rigor and patient-centered outcomes. The company maintains a focused mission to transform the therapeutic landscape through next-generation immunotherapies, underpinned by a commitment to advancing cytokine biology and translational medicine.